GlassScriptPhysician profile
Noelia Pena
NPI 1184198202
$1,394.00
in general payments reported to CMS, 2019-2025
20 companies · $587 in 2025
The $587 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $115 · 2022: $209 · 2023: $298 · 2024: $185 · 2025: $587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $996 · Education: $73.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $995.85 |
| Education | $73.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $233.54 | 2025 | Cobenfy |
| Alkermes, INC. | $213.32 | 2024-2025 | Aristada, Lybalvi |
| Janssen Biotech, INC. | $166.10 | 2021-2024 | Stelara, Simponi Aria, Remicade |
| Amgen INC. | $150.43 | 2022-2023 | Prolia, Evenity |
| Sobi, INC | $95.22 | 2023-2024 | |
| Teva Pharmaceuticals USA, INC. | $86.45 | 2025 | Austedo Xr, Uzedy |
| Glaxosmithkline, LLC. | $86.24 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $40.60 | 2025 | Invega Sustenna |
| Lilly USA, LLC | $37.69 | 2024 | Omvoh |
| Emd Serono, INC. | $37.65 | 2023 | Bavencio |
| Octapharma USA, INC. | $36.58 | 2023 | Panzyga |
| Merck Sharp & Dohme LLC | $31.03 | 2021-2023 | Keytruda |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.30 | 2023 | Spevigo |
| Genmab U.S., INC. | $27.49 | 2023 | Tivdak |
| Alnylam Pharmaceuticals INC. | $23.70 | 2023 | Onpattro |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.45 | 2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $22.32 | 2024 | |
| Grifols USA, LLC | $19.14 | 2024 | Gamunex-C |
| Gilead Sciences, INC. | $17.94 | 2025 | |
| Abbvie INC. | $16.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noelia Pena listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.